ArticleProceedings of the National Academy of Sciences of the United States of America2022
Human defensin-inspired discovery of peptidomimetic antibiotics.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Modulation of ESKAPE Bacteria Properties by NK-92 and NK-92-Derived LEVs: First Insights.International journal of molecular sciences · 2026Article
- Vm-MSI: a Vancomycin-Antimicrobial Peptide Conjugate Combating Resistant Bacteria and Broadening the Antimicrobial Spectrum.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Breaking disulfide bonds in a weakly bactericidal α-defensin unleashes a potent antimicrobial peptide with an altered conformation.PLoS pathogens · 2026Article
- Defensins as natural antimicrobial peptide scaffolds against antimicrobial-resistant pathogens: mechanisms, resistance risks, and translational prospects.Frontiers in cellular and infection microbiology · 2026Review
- Production and Functional Evaluation of Recombinant Active Peptide RH in Pichia Pastoris: Protection Against Escherichia Coli Induced Cell Death.Probiotics and antimicrobial proteins · 2026Article
- Heterologous expression and optimization of the antimicrobial peptide acidocin 4356 in Komagataella phaffii to target Pseudomonas aeruginosa.Applied microbiology and biotechnology · 2025Article
- Review
- Mechanism of antibacterial and antibiofilm of thiazolidinone derivative TD-H2-A against Staphylococcus aureus.Scientific reports · 2025Article
- Screening and identification of antimicrobial peptides from the gut microbiome of cockroach Blattella germanica.Microbiome · 2024Article
- Insights into the identification of antimicrobial peptides: A multidisciplinary observation.iMetaOmics · 2024Article
- Discovery of novel antibacterial agent for the infected wound treatment: all-hydrocarbon stapling optimization of LL-37.Theranostics · 2024Article
- Protective effect and mechanism of nanoantimicrobial peptide ND-C14 againstWorld journal of emergency medicine · 2024Article
- Roles of Lipopolysaccharide Glycosyltransferases in Maintenance ofInternational journal of molecular sciences · 2023Article
- Article
- The Anti-Amoebic Activity of a Peptidomimetic againstMicroorganisms · 2022Article
- Lights and Shadows on the Therapeutic Use of Antimicrobial Peptides.Molecules (Basel, Switzerland) · 2022Review
- β-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SignificanceWe report the development of peptidomimetic antibiotics derived from a natural antimicrobial peptide, human α-defensin 5. By engaging multiple bacterial targets, the lead compound is efficacious in vitro and in vivo against bacteria with highly inducible antibiotic resistance, promising a useful therapeutic agent for the treatment of infections caused by antibiotic-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.